Immune modulation could explain how experimental Alzheimer's therapy works

Posted by Leanne Kodsman on

In a July 8, 2013 press release, researchers at the University of Kentucky Sanders-Brown Center on Aging, led by Donna Wilcock, announced they have recently published a new paper in the Journal of Neuroscience detailing an advance in treatment for Alzheimer's disease.

The Gammagard IVIg is a therapy that has been investigated in the treatment of Alzheimer's, but was poorly understood. The UK researchers started investigating the mechanism in regard to how it acts in the brain to decrease deposits of amyloid, a key element in Alzheimer's pathology.


In a July 8, 2013 press release, researchers at the University of Kentucky Sanders-Brown Center on Aging, led by Donna Wilcock, announced they have recently published a new paper in the Journal of Neuroscience detailing an advance in treatment for Alzheimer's disease.

The Gammagard IVIg is a therapy that has been investigated in the treatment of Alzheimer's, but was poorly understood. The UK researchers started investigating the mechanism in regard to how it acts in the brain to decrease deposits of amyloid, a key element in Alzheimer's pathology.

Researchers introduced IVIg directly into the brains of mice that possessed the human gene which allows amyloid plaques to build. According to the press release, 'They found that IVIg lowers amyloid deposits in the brains of the mice over the course of seven days. Their data suggest that the modulation of inflammation in the brain by IVIg is a key event that leads to the reduction in amyloid deposition.'

The scientists hypothesize that the IVIg acts as an immune modulator.

This research shows that modulating the immune response within the brain will help ameliorate the Alzheimer's pathology.

    Innovative Research was established in 1998 after the realization that dependable, high-quality, and affordable research materials were hard to come by. Starting with core products like human plasma and serum, Innovative Research has grown to be a trusted supplier of all lab reagents, including human biologicals and ELISA kits. Today, we manufacture and supply thousands of high-quality human and animal biologicals including plasma, serum, tissues, and proteins.


Related Posts

ASSURED FLOW SOLUTIONS PARTNERS WITH INNOVATIVE RESEARCH TO DEVELOP TEST KITS TO HELP IN COVID-19 FIGHT
HOUSTON—10 April 2020 Assured Flow Solutions (AFS) is teaming up with Innovative Resear...
Read the Article
NOTICE: Grant Application Deadline has been extended to May 15, 2020
The past few weeks have been like nothing we have ever experienced, the COVID-19 pandem...
Read the Article
A Timeline of Hemophilia Research
Hemophilia is a bleeding disorder in which the body is unable to form blood clots prope...
Read the Article

← Older Post Newer Post →

×